PharmAla to supply Johns Hopkins Medicine for Clinical Trial
11 sept. 2024 08h55 HE
|
PharmAla Biotech
PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.
PharmAla Launches MDMA Clinical Trial Tool for Researchers
22 août 2024 09h07 HE
|
PharmAla Biotech
PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
09 août 2024 18h18 HE
|
PharmAla Biotech
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant
PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
30 juil. 2024 08h55 HE
|
PharmAla Biotech
PharmAla releases a comprehensive investor update following its Q3 financial release, including highlights such as a 10x revenue increase and patent update
PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
03 mai 2024 11h00 HE
|
PharmAla Biotech
PharmAla launches new educational resource for prescribers of MDMA through the Special Access Program
PharmAla Closes Private Placement and Concurrent Debt Settlement
19 avr. 2024 08h35 HE
|
PharmAla Biotech
PharmAla completes private placement and concurrent debt settlement with Advisor.
PharmAla Announces Private Placement and Concurrent Debt Settlement
10 avr. 2024 16h30 HE
|
PharmAla Biotech
PharmAla Initiates $750,000 Private Placement with concurrent debt settlement, anticipated to close on April 17th 2024
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
05 avr. 2024 08h58 HE
|
PharmAla Biotech
PharmAla Biotech announces that its Australian Joint Venture, Cortexa, has initiated manufacturing of LaNeo MDMA in Australia.
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
27 mars 2024 08h00 HE
|
PharmAla Biotech
PharmAla recieves Allowance from USPTO for its lead drug candidate, a next-generation MDMA composition paving the way for clinical trials
PharmAla Biotech Signs Sale Agreement with Numinus
26 mars 2024 08h55 HE
|
PharmAla Biotech
PharmAla announces binding sales order from Numinus Wellness, as well as a recent presentation of data to the Behaviour, Biology, and Chemistry Conference